Skila, which is backed by BelHealth Investment Partners, is merging wtih Mederi AG. Financial terms weren’t announced. Frankfurt, Germany-based Mederi provides pharmaceutical analytics and social network intelligence to life sciences companies. The new company will be called SkilaMederi.
Skila, a leading provider of fully managed “Solution as-a-Service” (SaaS) product launch and key opinion leader (KOL) management to pharmaceutical companies and Mederi AG of Frankfurt, Germany, a leading provider of pharmaceutical analytics and social network intelligence to life sciences companies, have announced their merger.
Skila’s solutions have been deployed in 61 countries, supporting numerous global brands, with more than 10 million user interactions and customers that include several of the top pharma companies.
Mederi is a leading provider of social analytics to the life sciences industry. Over the last six years, Mederi has created the globally leading information and analytics platform to explore healthcare networks and derive strategic and operational advice. Mederi’s clients are more successful in achieving regulatory approval, reimbursement and local brand uptake.
The new company will be called SkilaMederi and will become a leading provider of social analytics and launch management solutions for pharmaceutical companies. The SkilaMederi offering provides information on payer networks and tracks awareness towards brands and key concepts for reimbursement decisions. Based on the unique combination of information technology and strategic consulting, SkilaMederi will put the knowledge of thousands of local experts and virtually unlimited computational resources at the fingertips of every brand manager – delivering proven impact on the valuation of pharmaceutical pipelines.
Drew McCartney, Chief Executive Officer of SkilaMederi, said “by blending industry-leading stakeholder information, analytics and strategic advisory services with state-of-the-art technology and business process services, life science companies will experience an unparalleled ability to make better decisions more rapidly. The larger organization of SkilaMederi will eclipse past successes with their business intelligence approach that come together effectively at the customer’s doorstep.”
According to Kilian Weiss, Mederi’s CEO, “the merger brings together an incredible value proposition, providing a full spectrum of products and services that will accelerate the way pharma and biotech companies do business. Skila has a marquee customer base and very little overlap with Mederi’s and the merger creates significant cross marketing opportunities for both companies.” Simon Mason, President of SkilaMederi US commented, “providing our clients with a three dimensional view of key sentiment and relationship analysis, combined with the means to manage cause and effect, is a brand uptake tool of unprecedented power.”
“The combination with Mederi expands the growth potential of the combined company,” says Harold S. Blue, Managing Partner of BelHealth Investment Partners L.P., and Chairman of the Board of SkilaMederi. “Mederi’s social analytics platform is a new and exciting way for pharma companies to leverage the rapidly growing influence of social media in today’s business atmosphere.”
SkilaMederi will have a global presence with facilities in Frankfurt, Germany; Lviv, Ukraine; and headquarters in Morris Plains, New Jersey.